Orforglipron Explained: What the New Daily Weight-Loss Tablet Means in the UK

In short: Orforglipron is a once-daily tablet that works on the GLP-1 hormone pathway to reduce appetite. The MHRA authorised it in the UK in August 2026 (brand name Foundayo) for weight management in adults with a BMI of 30 or more, or 27 to under 30 with a weight-related health condition, and for type 2 diabetes. It is a prescription-only medicine, it is not currently available on the NHS while NICE completes its appraisal, and a prescriber must decide whether it is suitable for you.

This guide, written by a Ready Health prescribing pharmacist, explains what orforglipron is, how it differs from weekly injections, what the research shows and what side effects to be aware of.

What is orforglipron?

Orforglipron is a GLP-1 receptor agonist, the same broad class as semaglutide and liraglutide. Unlike those medicines, which are peptides, orforglipron is a small-molecule medicine. This is why it can be absorbed as a tablet without the strict fasting rules that apply to some other oral GLP-1 medicines. It is made by Eli Lilly, the company that also makes tirzepatide.

How does orforglipron work?

GLP-1 is a hormone your gut releases after eating. Medicines that mimic it can:

• act on appetite centres in the brain, so you feel less hungry and fuller sooner
• slow the rate at which your stomach empties
• help the body release insulin when blood sugar is high, which is why the class is also used in type 2 diabetes

Like other medicines in this class, it is licensed to be used alongside a reduced-calorie diet and increased physical activity, not instead of them.

Who is orforglipron licensed for in the UK?

According to the MHRA, orforglipron is authorised for weight loss and weight maintenance in adults with:

• a BMI of 30 kg/m² or more, or
• a BMI of 27 to under 30 kg/m² with at least one weight-related condition, such as high blood pressure, type 2 diabetes or sleep apnoea

It is also authorised to improve blood sugar control in adults with type 2 diabetes. Meeting the licence criteria does not automatically mean it is right for you: a prescriber will consider your medical history, other medicines, and any reasons it should be avoided, such as pregnancy or a history of pancreatitis.

How is orforglipron taken?

It is taken once a day, at any time of day, and the MHRA notes there are no food or water restrictions. Treatment starts at a low dose and is increased in steps, with at least one month at each step, to help the body adjust and limit side effects.

How does orforglipron compare with weekly injections and other tablets?

No head-to-head trial has yet compared orforglipron directly with the weekly injections, so it is not possible to say one is better for everyone. The choice depends on your health, preferences and how you tolerate treatment.

What did the research show?

In the ATTAIN-1 trial, published in 2025, adults with obesity but without diabetes took orforglipron or a placebo for 72 weeks alongside lifestyle advice. People on the highest dose studied lost, on average, around 11 to 12% of their body weight, compared with roughly 1 to 2% in the placebo group. Results varied between individuals, and some people stopped treatment because of side effects.

What are the side effects of orforglipron?

The most common side effects reported are digestive:

• nausea, vomiting and diarrhoea
• constipation
• indigestion and tummy pain

These are usually worse when starting or increasing the dose. As with all GLP-1 based medicines, there is a risk of rarer but serious problems such as acute pancreatitis and gallbladder problems. The MHRA strengthened its pancreatitis warning for this class in January 2026: get urgent medical help for severe, persistent tummy pain, especially if it spreads to the back. Suspected side effects can be reported through the MHRA Yellow Card scheme.

Is orforglipron available on the NHS?

Not at present. NICE is appraising orforglipron for obesity and overweight, with guidance expected in late 2026. Until NICE publishes its recommendation, NHS availability is not confirmed.

Frequently asked questions

Is orforglipron an injection?

No. It is a tablet taken once a day.

Do I need to take orforglipron on an empty stomach?

The MHRA states it can be taken at any time of day with no food or water restrictions. Always follow the patient information leaflet and your prescriber's instructions.

Can I take orforglipron if I am planning a pregnancy?

GLP-1 based medicines are not recommended during pregnancy or breastfeeding. Speak to your prescriber about contraception and how far ahead of trying to conceive any treatment should be stopped.

Is it safe to buy weight-loss tablets online without a consultation?

No. Orforglipron is a prescription-only medicine. Only obtain medicines through a registered UK pharmacy or clinic after a proper clinical assessment; the MHRA regularly warns about illegal and fake weight-loss products sold online.

Key takeaways

• Orforglipron is a once-daily GLP-1 tablet authorised by the MHRA in August 2026.
• It is licensed for adults with obesity, or overweight plus a weight-related condition, alongside diet and activity changes.
• Digestive side effects are common; pancreatitis is rare but serious.
• It is not currently on the NHS; NICE guidance is expected in late 2026.
• A prescriber must decide whether it, or any alternative, is suitable for you.

You may also find our guides on how semaglutide works for weight loss and how tirzepatide works for weight loss helpful.

Sources and further reading

• MHRA: UK first in Europe to authorise orforglipron
• NICE: orforglipron appraisal in development
• MHRA Drug Safety Update: GLP-1 medicines and acute pancreatitis
• MHRA: GLP-1 medicines for weight loss and diabetes - what you need to know

Last reviewed: October 2026 by Shamir Patel, Independent Prescribing Pharmacist, Ready Health. This article is general information and does not replace advice from your own clinician. Brand names are trademarks of their respective owners.

If you would like to talk through your weight-management options, you can book a weight-management consultation at Ready Health in Standish, Wigan. A prescriber will assess your health and discuss all suitable options with you, including whether any medicine is appropriate.